



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 07/11/2022

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

Subject: Submission of Standalone Unaudited Financial Results in compliance with Regulation 33 of SEBI (LODR) Regulations, 2015


Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Un-audited Financial Results of the Company for the Quarter ended on 30th September, 2022.
- 2) Limited Review Report on Standalone Un-audited Financial Results for the quarter ended on 30th September, 2022.

This is for your kind information and records..

Yours faithfully,
FOR NORRIS MEDICINES LIMITED


(VIMAL D. SHAH)
MANAGING DIRECTOR
DIN No. 01506655



General information about company	
Scrip code	524414
NSE Symbol	
MSEI Symbol	
ISIN*	INE744C01029
Name of company	NORRIS MEDICINES LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2022
Date of end of financial year	31-03-2023
Date of board meeting when results were approved	07-11-2022
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01-11-2022
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Medicines
Start date and time of board meeting	07-11-2022 11:00
End date and time of board meeting	07-11-2022 11:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Direct
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2022	01-04-2022
B	Date of end of reporting period	30-09-2022	30-09-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	302.78	398.09
	Other income	0	0
	Total income	302.78	398.09
2	Expenses		
(a)	Cost of materials consumed	216.92	252.69
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-41.64	-58.27
(d)	Employee benefit expense	60.38	104.52
(e)	Finance costs	64.8	74.07
(f)	Depreciation, depletion and amortisation expense	15.14	30.28
(f)	Other Expenses		
1	Other Expenses	43.49	95.02
10			
	Total other expenses	43.49	95.02
	Total expenses	359.09	498.31

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2022	01-04-2022
B	Date of end of reporting period	30-09-2022	30-09-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	-56.31	-100.22
4	Exceptional items	0	0
5	Total profit before tax	-56.31	-100.22
7	Tax expense		
8	Current tax	0	0
9	Deferred tax	0	0
10	Total tax expenses	0	0
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	-56.31	-100.22
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	-56.31	-100.22
22	Other comprehensive income net of taxes	0	0

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2022	01-04-2022
B	Date of end of reporting period	30-09-2022	30-09-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	-56.31	-100.22
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	992.58	992.58
	Face value of equity share capital	0	0
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	-0.56	1
	Diluted earnings (loss) per share from continuing operations	-0.56	1
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	-0.56	1
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.56	1
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results		

Statement of Asset and Liabilities	
Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022
Date of end of reporting period	30-09-2022
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
Assets	
1	Non-current assets
Property, plant and equipment	676.93
Capital work-in-progress	
Investment property	
Goodwill	0
Other intangible assets	0
Intangible assets under development	
Biological assets other than bearer plants	
Investments accounted for using equity method	
Non-current financial assets	
Non-current investments	0.94
Trade receivables, non-current	
Loans, non-current	-0.2
Other non-current financial assets	39.79
Total non-current financial assets	40.53
Deferred tax assets (net)	160.85
Other non-current assets	81.88
Total non-current assets	960.19
2	Current assets
Inventories	294.81
Current financial asset	
Current investments	0
Trade receivables, current	154.29
Cash and cash equivalents	1.86
Bank balance other than cash and cash equivalents	0
Loans, current	75.89
Other current financial assets	
Total current financial assets	232.04
Current tax assets (net)	
Other current assets	
Total current assets	526.85

Statement of Asset and Liabilities	
Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022
Date of end of reporting period	30-09-2022
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
Total assets	1487.04
Equity and liabilities	
Equity	
Equity attributable to owners of parent	
Equity share capital	992.58
Other equity	-2162.18
Total equity attributable to owners of parent	-1169.6
Non controlling interest	
Total equity	-1169.6
Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	1854.02
Trade payables, non-current	
Other non-current financial liabilities	
Total non-current financial liabilities	1854.02
Provisions, non-current	0
Deferred tax liabilities (net)	
Deferred government grants, Non-current	
Other non-current liabilities	
Total non-current liabilities	1854.02
Current liabilities	
Current financial liabilities	
Borrowings, current	296.45
Trade payables, current	192.34
Other current financial liabilities	42.28
Total current financial liabilities	531.07
Other current liabilities	
Provisions, current	271.55
Current tax liabilities (Net)	
Deferred government grants, Current	
Total current liabilities	802.62
3 Liabilities directly associated with assets in disposal group classified as held for sale	
4 Regulatory deferral account credit balances and related deferred tax liability	
Total liabilities	2656.64
Total equity and liabilities	1487.04
Disclosure of notes on assets and liabilities	

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2022	01-04-2022
Date of end of reporting period	30-09-2022	30-09-2022
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

Cash flow statement,direct		
Particulars		6 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022
B	Date of end of reporting period	30-09-2022
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
	Statement of cash flows	
	Cash flows from used in operating activities	
	Classes of cash receipts from operating activities	
	Receipts from sales of goods and rendering of services	0
	Receipts from royalties fees, commissions and other revenue	0
	Receipts from contracts held for dealing or trading purpose	0
	Receipts from premiums and claims annuities and other policy benefits	0
	Receipts from rents and subsequent sales of assets held for rental to others and subsequently held for sale	0
	Other cash receipts from operating activities	0
	Classes of cash payments from operating activities	
	Payments to suppliers for goods and services	0
	Payments from contracts held for dealing or trading purpose	0
	Payments to and on behalf of employees	0
	Payments for premiums and claims, annuities and other policy benefits	0
	Payments to manufacture or acquire assets held for rental to others and subsequently held for sale	0
	Other cash payments from operating activities	0
	Net cash flows from (used in) operations	0
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	0
	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	0
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from sales of intangible assets	0

Purchase of intangible assets	0
Proceeds from biological assets other than bearer plants	0
Purchase of biological assets other than bearer plants	0
Proceeds from sales of other long-term assets	0
Purchase of other long-term assets	0
Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Proceeds from government grants	0
Net cash flows from (used in) investing activities	0
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control	0
Payments from changes in ownership interests in subsidiaries that do not result in loss of control	0
Proceeds from issuing shares	0
Proceeds from issuing other equity instruments	0
Payments to acquire or redeem entity's shares	0
Payments of other equity instruments	0
Proceeds from exercise of stock options	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	0
Repayments of borrowings	0
Payments of finance lease liabilities	0
Payments of lease liabilities	0
Dividends paid	0
Interest paid	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) financing activities	0
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0
Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	0
Cash and cash equivalents cash flow statement at beginning of period	0
Cash and cash equivalents cash flow statement at end of period	0



Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended **30th Sep, 2022**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





H.N. JADAV & CO.
CHARTERED ACCOUNTANTS

CA Harishchandra N. Jadav
B. Com, FCA, DISA (ICAI)
Mobile : 98241 25540
harishnjadav@yahoo.com
harishnjadav@gmail.com

C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards , i.e. Indian Accounting Standard ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 07/11/2022

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat

For, H. N. JADAV & Co.
Chartered Accountants

CA HARISHCHANDRA JADAV

Proprietor
M. No. 040525
Firm Reg. No. 103801W
UDIN: 22040525BCMCBC9285

